Toronto, ON - A new manuscript published in JAMA from researchers at the University of Queensland, the University of Toronto, and the University of California, San Francisco, is raising concern about a fast-growing but poorly understood trend: the use of injectable peptides marketed online for enhancement purposes, often beyond the reach of traditional drug regulation.
Once largely confined to research and clinical development, synthetic peptides (e.g., BPC-157) are now widely promoted on social media platforms for muscle growth, injury recovery, anti-aging, and even cognitive enhancement. Their visibility has grown rapidly, with peptide-related content exceeding 130,000 posts on Instagram and drawing more than 230 million views on TikTok as of May 2026.
Yet, according to the authors, this surge in visibility and access is not matched by a corresponding evolution in regulatory oversight. Instead, peptides have emerged into what they describe as a "grey zone" spanning medicine, wellness, and illicit drug markets, making them difficult to classify, regulate, and monitor within existing frameworks.
"We are seeing peptides move rapidly from niche biomedical tools into mainstream consumer markets, largely without the scientific evidence or regulatory safeguards typically required for drugs," said Dr. Timothy Piatkowski of the University of Queensland. "The way these products are promoted online—often as safe and innovative solutions—creates a real public health blind spot, especially for young people."
Part of the challenge, the researchers argue, lies in the structure of modern peptide markets themselves. Some peptide-based medications are clinically approved and used in healthcare, while others are compounded under regulatory exemptions or sold directly online through telehealth services and "research chemical" vendors. This overlap blurs the line between legitimate treatment and enhancement use, complicating enforcement and creating uncertainty for clinicians, regulators, and consumers alike.
At the same time, regulatory approaches are struggling to keep pace. In some cases, tightening restrictions may unintentionally push consumers toward unregulated suppliers rather than reducing demand, while shifting policy signals can create confusion about what is permitted and safe.
"Current regulatory systems were not designed for substances that operate across medicine, wellness, and illicit markets simultaneously," said Dr. Kyle T. Ganson of the University of Toronto. "This creates instability and confusion, where changing rules may actually drive individuals toward unregulated and potentially riskier sources."
The digital environment is a central part of the issue. Social media platforms, influencer marketing, and direct-to-consumer supply chains are creating low-barrier access points that normalize enhancement practices and minimize perceived risks. These dynamics may be especially consequential for adolescent boys and young men, who are already exposed to appearance-related pressures online.
Despite the rapid expansion of peptide use, the authors emphasize that research on their health effects remains limited. Many compounds lack clinical trial data, and there is little population-level evidence on how, why, and among whom these substances are being used.
"We urgently need more research on how and why people are using peptides, as well as the potential health consequences," said Dr. Jason M. Nagata of the University of California, San Francisco. "Without a stronger evidence base and coordinated oversight, policy responses will continue to lag behind real-world use."
The researchers call for a more adaptive, system-wide policy response: one that extends beyond traditional drug control to address the digital ecosystems and market dynamics driving peptide use. Suggested approaches include stronger oversight of compounding practices, expanded monitoring of adverse effects, enforcement against deceptive online marketing, and greater investment in research and surveillance systems.
Without such changes, the authors warn, the gap between regulation and reality is likely to widen, leaving consumers exposed to unknown risks in a rapidly evolving, largely unregulated market.
The author group previously published an outline of key public health and clinical priorities to respond to the use of injectable peptides among young people.
AUSTRALIA
Timothy Piatkowski, PhD
School of Public Health and Centre for Community Health and Wellbeing
Faculty of Health, Medicine, and Behavioural Sciences
University of Queensland
Brisbane, Australia
